← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Humanetics Corporation
Edina, MN
$29,988,473
Total funding
10
Grants
Funding over time
peak $8.2M · FY2009–23$10M$7.5M$5M$2.5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
DOD$16,272,470 · 4
NIH$13,716,003 · 6
By mechanism
—$16,272,470 · 4
N01$10,299,178 · 1
N44$1,696,405 · 1
R43$1,495,529 · 3
R41$224,891 · 1
Investigators at Humanetics Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
DEVELOPMENT OF BIO 301 TO PREVENT ACUTE RADIATION SYNDROME AND MITIGATE THE DELAYED EFFECTS OF ACUTE RADIATION EXPOSURE$5,999,215
· FY2019 · Defense Health Agency
DEVELOPMENT OF BIO 300 INJECTABLE SUSPENSION TO TREAT RADIATION-INDUCED LUNG INJURY$5,132,520
· FY2022 · Defense Health Agency
DEVELOPMENT OF BIO 301: AN ENCAPSULATED NANOGENISTEIN THERAPY$3,811,222
· FY2017 · Department of the Army
SUPPLEMENTAL WORK-SARS-COV-2$2,641,049
N01 · FY2020 · AI
AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS$2,179,037
N01 · FY2019 · AI
SUPPLEMENTAL WORK-SARS-COV-2$1,872,652
N01 · FY2021 · AI
AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS$1,833,338
N01 · FY2020 · AI
AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS$1,773,102
N01 · FY2018 · AI
EXERCISE PHASE II TITLE: DEVELOPMENT OF BIO 300 AS A RADIATION MODULATOR FOR USE DURING RADIOTHERAPY OF LUNG CANCER ; PERIOD OF PERFORMANCE FROM 09/20/2012 TO 01/09/2016DUNS: 197085517CAN8478361$1,499,181
N44 · FY2014 · CA
COVID-19 TREATMENT WITH BIO 300 TO MITIGATE COVID-19 ASSOCIATED ACUTE RESPIRATORY DISTRESS SYNDROME AND RELATED SEQUELAE$1,329,513
· FY2021 · Defense Health Agency
Development of Cysteamine as a Medical Radiation Countermeasure$300,000
R43 · FY2010 · AI
Development of Cysteamine as a Medical Radiation Countermeasure$300,000
R43 · FY2009 · AI
Development of BIO 300 as a MCM for lethal radiation pneumonitis/fibrosis$299,035
R43 · FY2016 · AI
Development of BIO 300 as a novel treatment for idiopathic pulmonary fibrosis$298,474
R43 · FY2023 · HL
Development of BIO 300 as a MCM for lethal radiation pneumonitis/fibrosis$298,020
R43 · FY2017 · AI
Prevention of erectile dysfunction following prostate cancer radiotherapy$224,891
R41 · FY2014 · CA
Development of BIO300 as a Radiomodulator for Use During Radiation Therapy$197,224
N43 · FY2012 · CA